FluGen
Blood & Organ Banks · Wisconsin, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
597 Science Dr Ste 10, Madison, Wisconsi...Phone Number
(608) 441-2729Website
www.flugen.comRevenue
$8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
2
2
3
1
About FluGen
FluGen Inc. is dedicated to developing a more effective influenza vaccine, specifically the M2SR Vaccine Platform, which aims to address significant unmet needs in flu prevention. Their flagship candidate, the M2SR intranasal vaccine, is designed to stimulate a broad immune response and provide protection against both seasonal and drifted strains of the virus. The company targets the elderly and young populations who are most at risk from influenza and respiratory diseases. Additionally, FluGen is exploring the potential of the M2SR platform for protection against COVID-19 and other respiratory illnesses.Explore more
FluGen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is FluGen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once FluGen has new funding data
Website visits: Recent activity has been detected on your website
FluGen, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on FluGen recently announced quarterly report
Check out if FluGen is spiking on competitors!
Click to see if FluGen had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at FluGen
Product Launch: Get notified when FluGen launches new products
Check if FluGen has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined FluGen as Masked Content
Find 3 more new buyers
Compare Similar Companies to FluGen
Compare insights from companies similar to FluGen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
FluGen is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
FluGen is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about FluGen.
FluGen financials insights
Gather financial insights about FluGen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$3.2M
2015
Other Financing Round
$9.4M
2017
Series A
$2M
Debt
$5.5M
2021
Debt
$234K
FluGen Tech Stack
A closer look at the technologies used by FluGen
Most Recent Scoops
Funding
Project
Spending/Investment
Funding
FluGen has received an SBA PPP loan in the amount of $234,200 from BMO Harris Bank National Association resulting in the retention of 12 jobs.
Funding
Funding
Funding
FluGen recently secured $5.5 million in funding from investors. The company has raised $27 million to date.
Funding
Funding
Funding
FluGen News & Media
Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
PITTSBURGH, April 30, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by the United States Department of Defense (DoD).New Data Published in the Journal of Infectious Diseases Demonstrate FluGen's M2SR Vaccine Candidate Substantially Enhances Mucosal & Serum Antibodies Against Drifted Influenza Strains
Results show FluGen's investigational intranasal M2SR vaccine addresses an important unmet need by generating serum and mucosal antibodies against highly drifted strains of the H3N2 influenza virus MADISON, Wis., Nov. 9, 2022 /PRNewswire/ -- FluGen, Inc., a clinical-stage vaccine company...FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
– Four leading pediatric infectious disease institutions will study M2SR vaccine response in pediatric subjects, a population in which infection rates are often highest – – Collaborative study led by National Institute of Allergy and Infectious Diseases' "Collaborative Influenza Vaccine...FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults
– Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population – – Funded by the US Department of Defense, this study is expected to yield topline data in 2H 2022 – MADISON, Wis., June 22,...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding FluGen
Sign Up For FreeTo access detailed company insights
FluGen Inc. is dedicated to developing a more effective influenza vaccine, specifically the M2SR Vaccine Platform, which aims to address significant unmet needs in flu prevention. Their flagship candidate, the M2SR intranasal vaccine, is designed to stimulate a broad immune response and provide protection against both seasonal and drifted strains o... Read More
